What is the current stock price of ADC Therapeutics S.A. (ADCT)?

As of the latest market data, ADC Therapeutics S.A. (ADCT) is trading at $3.74. The stock has seen a loss of -0.53% today.

Does ADC Therapeutics S.A. (ADCT) pay a dividend?

Based on current data, ADC Therapeutics S.A. does not have a confirmed active dividend policy.

What is the market cap of ADC Therapeutics S.A.?

The current market capitalization of ADC Therapeutics S.A. (ADCT) is approximately unavailable.

ADCT

ADC Therapeutics S.A.·Healthcare

3.74

0.532%(−0.02)

Market Closed

3.93

5.080%(+0.19)

After Hours

Last Updated: — ET

52W L: $1.1352W H: $4.98

ADCT NEWS

prnewswire.com

Apr 1

ADC Therapeutics Announces New Employee Inducement Grant

LAUSANNE, Switzerland, April 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 17,000 of the Company's common shares to a new employee on April 1, 2026 ("Grant"). The Grant was offered as material inducement to the employee's employment.

seekingalpha.com

Mar 27

ADC Therapeutics SA (ADCT) Discusses ZYNLONTA Strategy, Clinical Progress, and Sales Growth Outlook Transcript

zacks.com

Mar 13

Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year?

Here is how ADC Therapeutics SA (ADCT) and ALX Oncology Holdings Inc. (ALXO) have performed compared to their sector so far this year.

seekingalpha.com

Mar 10

ADC Therapeutics SA (ADCT) Q4 2025 Earnings Call Transcript

zacks.com

Mar 10

ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.29 per share a year ago.

Company Profile

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Sector

Healthcare

Industry

Biotechnology

Employees

263

IPO Date

2020-05-18

Beta

1.95

Websitewww.adctherapeutics.com↗